<?xml version="1.0" encoding="UTF-8"?>
<p id="Par36">Second, our study included only centrally authorised products in the EU. However, due to the mandatory scope of the central procedure, the majority of new active substances approved during the study period is expected to be included in our study [
 <xref ref-type="bibr" rid="CR1">1</xref>]. In addition, the vast majority (80–98%) of medicines approved through national, mutual recognition and decentralised procedures concern non-innovator applications such as generics: in 2018, 80–98% of the applications submitted to the Coordination Group for Mutual Recognition and Decentralised Procedures over the year 2018 concerned non-innovator applications. We excluded non-innovator products as their EU-RMP should be in line with the EU-RMP of the reference product.
</p>
